Novo Nordisk Finance (Netherlands) B.V., founded in 1999 and based in Amsterdam, serves as the financing arm of Novo Nordisk A/S, a global leader in diabetes care and hormone replacement therapies. The company primarily focuses on providing financial support to its parent company's operations while managing a diverse portfolio of funding instruments.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| NOVOB 0.13% 2028-06-04 EURNovo Nordisk Finance (Netherlands) B.V. | Netherlands | 2028-06-04 | 0.125 | 2.40 |
| NOVOB 0.75% 2025-03-31 EURNovo Nordisk Finance (Netherlands) B.V. | Netherlands | 2025-03-31 | 0.750 | 0.00 |
| NOVOB 1.13% 2027-09-30 EURNovo Nordisk Finance (Netherlands) B.V. | Netherlands | 2027-09-30 | 1.125 | 2.35 |
| NOVOB 1.38% 2030-03-31 EURNovo Nordisk Finance (Netherlands) B.V. | Netherlands | 2030-03-31 | 1.375 | 2.72 |
| NOVOB 3.13% 2029-01-21 EURNovo Nordisk Finance (Netherlands) B.V. | Netherlands | 2029-01-21 | 3.125 | 2.56 |
| NOVOB 3.25% 2031-01-21 USDNovo Nordisk Finance (Netherlands) B.V. | Netherlands | 2031-01-21 | 3.250 | 2.87 |
| NOVOB 3.38% 2026-05-21 EURNovo Nordisk Finance (Netherlands) B.V. | Netherlands | 2026-05-21 | 3.375 | 2.33 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Historically, Novo Nordisk Finance has been a significant player in the bond market, issuing its first bonds in 2000. Notable issuances include a €1 billion 10-year bond in 2019, which was well-received and reflects competitive yields compared to industry standards. Most recently, the issuer has focused on sustainability-linked bonds, aligning with the parent company’s commitment to environmental responsibility. Current yields remain attractive for investors seeking stable returns in a low-interest-rate environment.